BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19496616)

  • 1. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
    Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
    Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate.
    Xing L; Devadas B; Devraj RV; Selness SR; Shieh H; Walker JK; Mao M; Messing D; Samas B; Yang JZ; Anderson GD; Webb EG; Monahan JB
    ChemMedChem; 2012 Feb; 7(2):273-80. PubMed ID: 22174080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
    Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
    J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.
    Selness SR; Devraj RV; Devadas B; Walker JK; Boehm TL; Durley RC; Shieh H; Xing L; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Messing D; Yang J; Mao MK; Yalamanchili G; Vonder Embse R; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
    Bioorg Med Chem Lett; 2011 Jul; 21(13):4066-71. PubMed ID: 21641211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
    Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
    Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
    Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of p38alpha active mutants reveal conformational changes in L16 loop that induce autophosphorylation and activation.
    Diskin R; Lebendiker M; Engelberg D; Livnah O
    J Mol Biol; 2007 Jan; 365(1):66-76. PubMed ID: 17059827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
    Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.
    Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
    Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
    J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies for inhibition of the p38 MAPK pathway.
    Zhang J; Shen B; Lin A
    Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.